CLINICAL TRIALS PROFILE FOR LYMPHOSEEK KIT
✉ Email this page to a colleague
All Clinical Trials for LYMPHOSEEK KIT
Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
---|---|---|---|---|---|---|
NCT00671918 ↗ | Trial of Lymphoseek in Intraoperative Localization of Lymph Nodes in Breast Cancer and Melanoma | Completed | Navidea Biopharmaceuticals | Phase 3 | 2008-04-01 | Data from this pivotal clinical trial will be used to support a marketing application (i.e., NDA) for Navidea's Lymphoseek for use in intraoperative localization of lymph tissue (nodes) in the lymphatic pathway draining the primary site of a tumor. |
NCT00911326 ↗ | Evaluation of Sentinel Lymph Nodes in Head and Neck Squamous Cell Carcinoma | Terminated | Navidea Biopharmaceuticals | Phase 3 | 2009-05-01 | The purpose of this study is to determine the false negative rate (FNR) associated with Lymphoseek-identified sentinel lymph nodes (SLNs) relative to the pathological status of non-sentinel lymph nodes in elective neck dissection (END) in head & neck squamous cell carcinoma (HNSCC). NEO3-06 (this study) is a Phase 3 clinical trial designed to supplement NEO3-05, a completed Phase 3 clinical trial conducted in patients with breast cancer or melanoma. NEO3-05 was designed to establish Lymphoseek as an effective radio-diagnostic agent to be used in the intraoperative localization of lymph tissue (nodes) in the lymphatic pathway draining the primary site of a tumor. |
NCT01106040 ↗ | Breast and Melanoma Trial With Lymphoseek to Identify Lymph Nodes | Completed | Navidea Biopharmaceuticals | Phase 3 | 2010-06-01 | Data from this pivotal clinical trial will be used to support a marketing application (i.e., NDA) of Navidea's Lymphoseek for use in anatomical delineation of lymphoid tissue (nodes) in the lymphatic pathway draining the primary site of a tumor. Multicenter, open-label, within-patient comparative study of Lymphoseek and vital blue dye in the detection of excised lymph nodes in patients with known melanoma and breast cancer. All patients will receive a single dose of 50 µg Lymphoseek radiolabeled with 0.5 or 2.0 mCi Tc 99m and vital blue dye. |
>Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for LYMPHOSEEK KIT
Condition Name
Clinical Trial Locations for LYMPHOSEEK KIT
Trials by Country
Clinical Trial Progress for LYMPHOSEEK KIT
Clinical Trial Phase
Clinical Trial Sponsors for LYMPHOSEEK KIT
Sponsor Name